Icatibant Viatris: Uses, Dosage & Side Effects
A bradykinin B2 receptor antagonist for the acute treatment of hereditary angioedema (HAE) attacks in adults with C1-esterase inhibitor deficiency
Icatibant Viatris is a prescription medication used to treat acute attacks of hereditary angioedema (HAE) in adults. Hereditary angioedema is a rare genetic disorder caused by a deficiency or dysfunction of C1-esterase inhibitor, leading to excessive bradykinin production and recurrent episodes of severe swelling. Icatibant works by selectively blocking the bradykinin B2 receptor, thereby reversing the vascular permeability that causes tissue swelling. It is administered as a single 30 mg subcutaneous injection using a pre-filled syringe and can be self-administered at home after proper training. Symptom relief typically begins within 30 to 60 minutes. Icatibant Viatris is a generic version of the original brand Firazyr, containing the same active substance with proven bioequivalence.
Quick Facts: Icatibant Viatris
Key Takeaways About Icatibant Viatris
- Targeted acute treatment: Icatibant Viatris is specifically designed to treat acute HAE attacks by blocking the bradykinin B2 receptor, the key driver of swelling in hereditary angioedema
- Rapid onset of action: Symptom relief typically begins within 30-60 minutes after subcutaneous injection, making it effective as an on-demand rescue treatment
- Self-administration at home: After proper training, patients can self-inject using the pre-filled syringe at the first signs of an attack, enabling early treatment
- Well-established safety profile: The most common side effects are injection site reactions (redness, swelling, itching), which are generally mild and self-limiting
- Generic equivalent: Icatibant Viatris is bioequivalent to the original brand Firazyr, offering the same efficacy and safety at a potentially lower cost
What Is Icatibant Viatris and What Is It Used For?
Icatibant Viatris is a bradykinin B2 receptor antagonist used for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults with C1-esterase inhibitor deficiency. It works by blocking the effects of bradykinin, the molecule responsible for causing the characteristic swelling of HAE.
Hereditary angioedema (HAE) is a rare autosomal dominant genetic disorder that affects approximately 1 in 50,000 people worldwide. The condition is caused by mutations in the SERPING1 gene, which encodes the C1-esterase inhibitor (C1-INH) protein. When C1-INH is deficient (Type I HAE) or dysfunctional (Type II HAE), the contact activation (kallikrein-kinin) system becomes dysregulated, leading to excessive production of bradykinin. Bradykinin binds to B2 receptors on endothelial cells, increasing vascular permeability and causing the characteristic episodes of subcutaneous and submucosal swelling.
HAE attacks can affect virtually any part of the body but most commonly involve the extremities (hands, feet, arms, legs), the face and lips, the gastrointestinal tract (causing severe abdominal pain, nausea, and vomiting), and the upper airway (potentially life-threatening laryngeal swelling). Attacks typically develop over several hours, peak over 12-36 hours, and resolve spontaneously over 2-5 days without treatment. However, with acute treatment such as icatibant, symptom resolution can be dramatically accelerated.
Icatibant is a synthetic decapeptide that acts as a selective, competitive antagonist at the bradykinin B2 receptor. By occupying the B2 receptor and preventing bradykinin from binding, icatibant blocks the signal that causes increased vascular permeability and tissue swelling. This mechanism of action is highly specific to the pathophysiology of HAE, making icatibant a targeted therapy for this condition.
Icatibant Viatris is a generic version of the original brand Firazyr, which was first approved by the European Medicines Agency (EMA) in 2008. Both products contain the same active substance (icatibant acetate 30 mg), are administered in the same way, and have demonstrated bioequivalence. Icatibant Viatris has undergone rigorous regulatory evaluation to ensure it meets the same quality, safety, and efficacy standards as the reference product.
How does Icatibant Viatris work?
The mechanism of action of icatibant is centred on the bradykinin pathway. In patients with HAE, the deficiency or dysfunction of C1-INH leads to uncontrolled activation of plasma kallikrein, which cleaves high-molecular-weight kininogen to release bradykinin. Bradykinin then binds to B2 receptors on vascular endothelial cells, triggering a cascade of intracellular signalling events that lead to increased vascular permeability, vasodilation, and fluid extravasation into surrounding tissues, resulting in angioedema.
Icatibant competes with bradykinin for binding to the B2 receptor, effectively blocking the downstream effects. Unlike C1-INH replacement therapies (which work upstream by restoring the missing inhibitor), icatibant acts at the final common pathway of angioedema pathogenesis. This targeted approach means that icatibant works regardless of the upstream trigger, making it effective for all types of bradykinin-mediated angioedema associated with C1-INH deficiency.
After subcutaneous injection of 30 mg, icatibant reaches peak plasma concentration within approximately 30 minutes. It has a bioavailability of approximately 97% and is rapidly distributed, with a volume of distribution of approximately 29 litres. The terminal half-life is approximately 1-2 hours, and the drug is metabolized by proteolytic enzymes to inactive metabolites that are primarily excreted through the kidneys.
What Should You Know Before Taking Icatibant Viatris?
Before taking Icatibant Viatris, inform your doctor about any allergies, heart conditions (especially acute ischaemic heart disease or unstable angina), if you are pregnant or breastfeeding, and all other medications you are taking, particularly ACE inhibitors. Icatibant should be used with caution in patients with acute coronary disease.
Contraindications
Icatibant Viatris is contraindicated in patients with known hypersensitivity to icatibant or any of the excipients in the formulation. While true allergic reactions to icatibant are extremely rare, patients should be aware of the ingredients in the product and report any previous adverse reactions to similar medications to their healthcare provider.
There are no absolute contraindications based on age (within the approved adult population), organ function, or concomitant diseases. However, certain clinical situations require particular caution and close medical supervision, as outlined in the warnings and precautions section below.
Warnings and Precautions
Patients with acute ischaemic heart disease or unstable angina pectoris should be treated under close medical supervision. Icatibant blocks the bradykinin B2 receptor, and bradykinin plays a role in cardiovascular physiology, including coronary vasodilation and myocardial protection during ischaemia. Theoretically, blocking B2 receptors during an acute coronary event could interfere with these protective mechanisms, although clinical evidence of harm in this setting is limited.
Patients who have recently had a stroke should also be monitored carefully for the same reasons. The prescribing physician should carefully weigh the benefits of treating an acute HAE attack against the theoretical cardiovascular risks in these patient populations.
Laryngeal attacks require special attention. While icatibant is effective for laryngeal HAE attacks, patients experiencing throat or airway swelling should always seek immediate emergency medical attention in addition to self-administering icatibant. Laryngeal angioedema can be life-threatening, and icatibant should not be relied upon as the sole treatment in cases of severe airway compromise. Emergency airway management may be necessary.
If you are taking an ACE (angiotensin-converting enzyme) inhibitor for high blood pressure or heart failure, be aware that icatibant may theoretically reduce the antihypertensive effect of ACE inhibitors. This is because ACE inhibitors work partly by increasing bradykinin levels, and icatibant blocks the effects of bradykinin. Inform your doctor if you take ACE inhibitors, and monitor your blood pressure as advised.
Pregnancy and Breastfeeding
Icatibant Viatris is not recommended during pregnancy unless clearly necessary. There is very limited data on the use of icatibant in pregnant women. Animal reproductive toxicity studies have shown some adverse effects at doses significantly higher than the therapeutic dose in humans, including delayed parturition (due to the role of bradykinin in the initiation of labour). Women of childbearing potential should use effective contraception during treatment.
It is not known whether icatibant is excreted in human breast milk. Animal studies have shown that icatibant and its metabolites are excreted in milk. As a precautionary measure, breastfeeding should be avoided for 12 hours after administration of icatibant. Your physician will help you decide whether the benefits of treatment outweigh any potential risks to the infant.
If you are pregnant, suspect you may be pregnant, planning to become pregnant, or breastfeeding, consult your doctor before using this medication. HAE management during pregnancy requires careful specialist oversight, as attack frequency may change during pregnancy, and treatment choices must be individualised.
Children and Adolescents
Icatibant Viatris is approved for use in adults (18 years and older). The safety and efficacy of icatibant in children and adolescents under 18 years of age have not been established in the context of the Icatibant Viatris product. However, the reference product (Firazyr) has some data supporting use in paediatric patients aged 2 years and older. For paediatric HAE management, consult a specialist in hereditary angioedema who can advise on appropriate treatment options.
How Does Icatibant Viatris Interact with Other Drugs?
No formal drug interaction studies have been performed with icatibant. The most clinically relevant potential interaction is with ACE inhibitors, where icatibant may theoretically reduce the antihypertensive effect. Icatibant is not metabolized by cytochrome P450 enzymes, reducing the risk of metabolic drug interactions.
Icatibant is a synthetic peptide that is degraded by proteolytic enzymes rather than being metabolized through the cytochrome P450 (CYP) enzyme system. This means that traditional drug-drug interactions mediated through CYP enzyme inhibition or induction are not expected. Similarly, icatibant is not expected to affect the metabolism of other drugs that are CYP substrates.
The primary pharmacological interaction of clinical interest involves ACE inhibitors. ACE (angiotensin-converting enzyme) is also known as kininase II, and one of its important biological functions is the degradation of bradykinin. ACE inhibitors therefore increase bradykinin levels as part of their mechanism of action. Since icatibant blocks the bradykinin B2 receptor, concurrent use may reduce the bradykinin-mediated component of the ACE inhibitor's therapeutic effect, potentially attenuating its antihypertensive and cardioprotective benefits.
| Drug / Class | Type of Interaction | Clinical Significance | Recommendation |
|---|---|---|---|
| ACE Inhibitors (e.g., enalapril, ramipril, lisinopril) | Pharmacodynamic antagonism | Moderate – may reduce antihypertensive effect | Monitor blood pressure; inform treating physician |
| C1-INH Replacement (e.g., Berinert, Cinryze) | Complementary mechanism | Low – different targets in the same pathway | May be used in combination under specialist guidance |
| Androgens (e.g., danazol) | No direct interaction expected | Low – different mechanisms of action | Can be used concurrently; androgens are for prophylaxis, icatibant for acute attacks |
| Tranexamic acid | No direct interaction expected | Low | Can be used alongside; consult specialist |
| Oral contraceptives / HRT | No interaction expected | Low | No dose adjustment needed; note oestrogen may trigger HAE attacks |
Major Interactions
There are no major (high-severity) drug interactions that absolutely contraindicate the use of icatibant with other medications. The interaction with ACE inhibitors is the most clinically relevant but is classified as moderate in severity. In practice, HAE patients are infrequently prescribed ACE inhibitors because this drug class is known to elevate bradykinin levels and may worsen or trigger angioedema episodes in susceptible individuals.
Minor Interactions
No clinically significant minor drug interactions have been identified in clinical studies or post-marketing surveillance. Because icatibant is used on an as-needed (acute) basis rather than as a chronic daily medication, the opportunity for sustained drug interactions is limited. Each dose of icatibant has a relatively short half-life (1-2 hours), further reducing the window for potential interactions.
What Is the Correct Dosage of Icatibant Viatris?
The recommended dose of Icatibant Viatris is one subcutaneous injection of 30 mg (the entire contents of one pre-filled syringe), administered into the abdominal area at the first signs of an HAE attack. If symptoms recur or do not resolve adequately, up to two additional injections may be given at intervals of at least 6 hours, with a maximum of 3 injections (90 mg) in 24 hours.
Adults
Standard Adult Dose
Dose: 30 mg (one pre-filled syringe of 3 mL)
Route: Subcutaneous injection into the abdominal area
Frequency: Single injection at onset of attack; may repeat after 6 hours if needed
Maximum: 3 injections (90 mg) per 24 hours
Treatment should be initiated as early as possible at the first recognisable signs of an HAE attack. Patients who have been trained in self-administration should carry their medication with them at all times to enable prompt treatment. The injection should be administered slowly into the subcutaneous tissue of the abdominal wall, approximately 5-10 cm below the navel, avoiding areas of scarring or bruising.
In most clinical trials, a single injection of 30 mg was sufficient to treat an attack. The FAST-1 and FAST-2 clinical trials demonstrated that the median time to onset of symptom relief was approximately 2 hours, with time to near-complete symptom relief ranging from 3 to 8 hours depending on the location and severity of the attack. If symptoms return or insufficient relief is achieved after the first injection, a second dose may be administered after at least 6 hours, and a third dose after a further 6 hours if necessary.
| Patient Group | Dose | Maximum in 24h | Notes |
|---|---|---|---|
| Adults (18+) | 30 mg SC | 90 mg (3 injections) | Min. 6 hours between doses |
| Elderly (65+) | 30 mg SC | 90 mg (3 injections) | No dose adjustment needed; limited data |
| Renal impairment | 30 mg SC | 90 mg (3 injections) | No dose adjustment needed |
| Hepatic impairment | 30 mg SC | 90 mg (3 injections) | No dose adjustment needed |
| Children (<18) | Not established | N/A | Not approved for paediatric use (Icatibant Viatris) |
Children
Icatibant Viatris is not approved for use in children and adolescents under 18 years of age. The safety and efficacy of this specific product have not been established in the paediatric population. Paediatric HAE patients should be managed by a specialist who can recommend appropriate alternative acute treatments, such as C1-esterase inhibitor concentrates, which are approved for paediatric use. The reference product Firazyr has some approved paediatric indications in certain markets, with weight-based dosing for patients aged 2 years and older.
Elderly
No dose adjustment is required for elderly patients (65 years and older). Clinical experience with icatibant in patients over 65 years is limited, but the available data do not suggest that dose modification is necessary based on age alone. Elderly patients should be monitored for co-morbid conditions, particularly cardiovascular disease, as outlined in the precautions section. The overall safety profile in elderly patients appears similar to that observed in younger adults.
Missed Dose
Icatibant Viatris is an on-demand acute treatment, not a regularly scheduled medication. It is administered only when an HAE attack occurs. There is no concept of a "missed dose" in the traditional sense. However, it is critically important that patients always have their supply of icatibant available and carry it with them, especially when travelling. Expired or depleted supplies should be replaced promptly. If a patient experiences an HAE attack and does not have icatibant available, they should seek immediate medical attention, particularly if the attack involves the larynx or abdomen.
Overdose
No cases of clinically significant overdose with icatibant have been reported. In clinical pharmacology studies, healthy volunteers received doses up to 3.2 mg/kg (approximately 7 times the therapeutic dose) intravenously without serious adverse effects. The most notable findings at supratherapeutic doses were local injection site reactions and, at very high doses, transient reductions in blood pressure. There is no specific antidote for icatibant overdose. In the event of suspected overdose, treatment should be supportive and symptomatic, with appropriate monitoring of vital signs and clinical status.
What Are the Side Effects of Icatibant Viatris?
The most common side effects of Icatibant Viatris are injection site reactions, occurring in over 90% of patients. These include redness (erythema), swelling, warmth, pain, itching, and a burning sensation at the injection site. These reactions are generally mild to moderate and resolve within a few hours. Systemic side effects such as nausea, headache, and fever are less common.
Like all medicines, Icatibant Viatris can cause side effects, although not everybody gets them. The safety profile of icatibant has been well characterised in clinical trials (FAST-1, FAST-2, FAST-3) and extensive post-marketing surveillance. Injection site reactions are by far the most frequently observed adverse effect and are considered a class effect of subcutaneous peptide injections. These reactions are typically self-limiting and rarely require any specific treatment.
The overall safety profile is favourable, particularly when considered in the context of the serious nature of HAE attacks that icatibant is used to treat. Serious adverse events directly attributable to icatibant are rare. Below is a detailed breakdown of side effects by frequency, according to the standard classification used by the EMA.
Very Common (affects more than 1 in 10 patients)
- Injection site reactions: erythema (redness)
- Injection site reactions: swelling
- Injection site reactions: warmth/burning sensation
- Injection site reactions: pain
- Injection site reactions: itching (pruritus)
- Injection site reactions: induration (hardening)
Common (affects 1 to 10 in 100 patients)
- Nausea
- Headache
- Dizziness
- Pyrexia (fever)
- Elevated transaminases (liver enzymes)
- Rash
Uncommon (affects 1 to 10 in 1,000 patients)
- Urticaria (hives)
- Malaise (general feeling of unwellness)
- Asthenia (weakness/fatigue)
Not Known (frequency cannot be estimated from available data)
- Hypersensitivity reactions (very rare reports from post-marketing surveillance)
Injection site reactions deserve particular discussion because of their very high frequency. In clinical trials, approximately 97% of patients experienced at least one injection site reaction. The reactions typically begin within minutes of the injection, peak within 15-30 minutes, and resolve completely within 1-3 hours. The severity is generally mild (grade 1) to moderate (grade 2). Applying a cold pack to the injection site before and after the injection may help reduce discomfort. Importantly, the high frequency of injection site reactions does not appear to deter patients from continuing to use icatibant for subsequent attacks, and the reactions do not appear to worsen with repeated use.
While most side effects of icatibant are mild, seek immediate medical attention if you experience signs of a severe allergic reaction (anaphylaxis) such as widespread skin rash, difficulty breathing, swelling of the face or throat, rapid heartbeat, or a sudden drop in blood pressure. Also seek emergency care if your HAE attack involves the throat or airway, even after administering icatibant, as airway compromise can be life-threatening and may require additional emergency treatment.
Long-term safety
Long-term safety data from open-label extension studies and post-marketing surveillance spanning more than 15 years of clinical use have not revealed any new safety signals or cumulative toxicity concerns. Patients have safely self-administered icatibant for multiple attacks over periods of several years without evidence of increased adverse effects, tachyphylaxis (loss of effectiveness), or antibody formation against the drug. There is no evidence of immunogenicity, which is noteworthy given that icatibant is a synthetic peptide.
How Should You Store Icatibant Viatris?
Store Icatibant Viatris below 25°C in the original packaging to protect from light. Do not freeze. The pre-filled syringe should not be used if the solution is cloudy, discoloured, or contains particles. Always check the expiry date before use and keep out of reach of children.
Proper storage of Icatibant Viatris is essential to ensure the medication remains effective when needed. Since HAE attacks are unpredictable and require prompt treatment, patients should always ensure they have at least one or two unexpired pre-filled syringes readily available.
- Temperature: Store below 25°C (77°F). Do not refrigerate or freeze.
- Light protection: Keep in the original carton to protect from light.
- Do not freeze: Freezing may damage the solution and the syringe mechanism.
- Shelf life: Check the expiry date printed on the carton and syringe label. Do not use after the stated expiry date.
- Inspection: Before use, visually inspect the solution. It should be a clear, colourless liquid. Do not use if cloudy, discoloured, or containing visible particles.
- Disposal: Do not throw away the used syringe in household waste. Dispose of in a sharps container according to local regulations, or return to your pharmacy for safe disposal.
- Keep out of reach of children.
When travelling, store Icatibant Viatris in a cool bag if temperatures exceed 25°C, but ensure it does not freeze. For air travel, carry the medication in your hand luggage with a copy of your prescription or a letter from your doctor. Having your medication readily accessible is crucial, as HAE attacks can occur at any time and require prompt treatment.
What Does Icatibant Viatris Contain?
Each pre-filled syringe of Icatibant Viatris contains 30 mg of icatibant (as acetate) in 3 mL of solution. The excipients include sodium chloride, acetic acid (glacial), sodium hydroxide (for pH adjustment), and water for injections.
Active Ingredient
The active substance is icatibant, present as icatibant acetate. Each pre-filled syringe contains 30 mg of icatibant in 3 mL of solution, corresponding to a concentration of 10 mg/mL. Icatibant is a synthetic decapeptide (consisting of 10 amino acids) with a molecular weight of approximately 1,304 daltons. It is structurally related to bradykinin but has been modified to act as a competitive antagonist rather than an agonist at the B2 receptor.
Excipients (Inactive Ingredients)
- Sodium chloride: Used to make the solution isotonic (matching the body's natural salt concentration) for comfortable injection
- Acetic acid (glacial): pH buffer to maintain the stability and solubility of icatibant
- Sodium hydroxide: Used for pH adjustment to approximately 5.5
- Water for injections: Solvent
The formulation does not contain any preservatives, latex, or common allergens. The pre-filled syringe is made of Type I borosilicate glass with a stainless steel needle and rubber plunger stopper. Patients with known allergies to any of the excipients should inform their healthcare provider before use.
Frequently Asked Questions About Icatibant Viatris
Icatibant Viatris is used for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults with C1-esterase inhibitor deficiency. HAE is a rare genetic condition that causes episodes of severe swelling in the hands, feet, face, abdomen, and airway. Icatibant works by blocking the bradykinin B2 receptor, the key mediator responsible for the swelling in HAE attacks. It provides rapid symptom relief, typically within 30-60 minutes of injection.
Icatibant Viatris typically begins to provide symptom relief within 30 to 60 minutes after subcutaneous injection. In clinical trials, the median time to onset of symptom relief was approximately 2 hours, with clinically meaningful improvement within the first few hours. Early treatment at the first signs of an attack tends to lead to faster and more complete resolution of symptoms. Without treatment, HAE attacks can last 2-5 days.
Yes, Icatibant Viatris is designed for self-administration. After receiving appropriate training from a healthcare professional on subcutaneous injection technique, patients can self-inject at home when an HAE attack occurs. The medication comes in a pre-filled syringe that is ready to use. It should be injected slowly into the subcutaneous tissue of the abdominal area. Patients should always carry at least one pre-filled syringe with them to ensure prompt treatment of unexpected attacks.
Icatibant Viatris is a generic version of the original brand Firazyr. Both contain the same active substance (icatibant acetate 30 mg) and are administered the same way (subcutaneous injection). Icatibant Viatris has been approved after demonstrating bioequivalence with Firazyr, meaning it provides the same therapeutic effect. The primary difference is typically the price, with generic versions generally being more cost-effective. Both products have the same safety and efficacy profile.
Icatibant Viatris is not recommended during pregnancy unless clearly necessary. There is limited data on its use in pregnant women, and animal studies have shown some reproductive effects at high doses. Bradykinin plays a role in the initiation of labour, so blocking the B2 receptor could theoretically affect this process. Pregnant women with HAE should be managed by a specialist who can recommend the safest treatment options, which may include C1-INH concentrates that have more established pregnancy safety data.
Store Icatibant Viatris below 25°C in the original packaging to protect it from light. Do not freeze the product. Before use, check that the solution is clear and colourless without any particles. Always check the expiry date and do not use expired medication. When travelling, keep the medication in a cool bag if temperatures exceed 25°C, and always carry it in your hand luggage on flights. Keep out of reach of children and dispose of used syringes in a sharps container.
References
- European Medicines Agency (EMA). Icatibant Viatris – Summary of Product Characteristics. EMA, 2024. Available from: www.ema.europa.eu
- Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update. World Allergy Organization Journal. 2022;15(3):100627. doi:10.1016/j.waojou.2022.100627
- Lumry WR, Li HH, Levy RJ, et al. Icatibant for multiple hereditary angioedema attacks across the controlled and open-label extension phases of FAST-3. International Archives of Allergy and Immunology. 2015;168(1):44-55. doi:10.1159/000441060
- Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. New England Journal of Medicine. 2010;363(6):532-541. doi:10.1056/NEJMoa0906393
- Bork K, Bernstein JA, Engel R. Hereditary angioedema: a review of the current treatment landscape. Journal of Allergy and Clinical Immunology: In Practice. 2024;12(4):887-897.
- Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. New England Journal of Medicine. 2010;363(6):513-522.
- Riedl MA, Bernstein JA, Li H, et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: Phase 3, randomized, placebo-controlled trial. Annals of Allergy, Asthma & Immunology. 2014;112(2):163-169.
- Busse PJ, Christiansen SC. Hereditary Angioedema. New England Journal of Medicine. 2020;382(12):1136-1148. doi:10.1056/NEJMra1808012
- US Hereditary Angioedema Association (HAEA). Medical Advisory Board 2019 Guidelines for the Management of Hereditary Angioedema. HAEA, 2020.
- World Health Organization (WHO). Model List of Essential Medicines – 23rd List, 2023. Geneva: WHO, 2023.
Medical Editorial Team
Medical Content
Written by iMedic Medical Editorial Team – specialists in immunology, clinical pharmacology, and rare diseases
Medical Review
Reviewed by iMedic Medical Review Board according to international guidelines (EMA, WAO/EAACI, FDA)
Evidence Level
Grade 1A – based on systematic reviews and randomized controlled trials (FAST-1, FAST-2, FAST-3)
Independence
No pharmaceutical company funding or sponsorship. Independent medical editorial content.
Last medically reviewed: | First published:
Our Editorial Standards
All medical content on iMedic is written and reviewed by qualified healthcare professionals. We follow a rigorous editorial process:
- Evidence-based: All claims are supported by peer-reviewed research and international clinical guidelines
- Expert-reviewed: Content is reviewed by board-certified physicians with relevant specialty expertise
- Regularly updated: Content is reviewed at least annually and updated when new evidence or guidelines are published
- Transparent: We clearly cite our sources and disclose any potential conflicts of interest
- Accessible: Written in clear, patient-friendly language while maintaining clinical accuracy
Learn more about our editorial standards and medical team.